NEW YORK and LONDON, April 13, 2021 – Tiziana Life Sciences plc (NASDAQ: TLSA; LSE: TILS), today announced that its former subsidiary, Accustem Sciences Limited (“Accustem”), intends to file a
Tiziana Plans Phase 2 Clinical Study in Moderate to Severe Covid-19 Patients with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
Gabriele Cerrone, Chairman of Tiziana Life Sciences, to give an interview on Bloomberg Television US at 1:20 PM ET Today
EQTEC plc (AIM: EQT), a world-leading gasification technology solutions company for sustainable waste-to-energy projects, is pleased to provide the following trading update.
Update on migration of uncertificated shares from CREST to the Euroclear Bank system
EQTEC plc (AIM: EQT), a world-leading gasification technology solutions company for sustainable waste-to-energy projects , is pleased to announce that it has signed a Collaboration Framework Agreement (the “Agreement”) with
Tiziana Life Sciences Interview to Air on Bloomberg Television US on the RedChip Money Report
Tiziana Life Sciences to Present at the BIO CEO & Investor Digital Conference
NEW YORK and LONDON – February 5, 2021 (GLOBE NEWSWIRE) – Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative
Tiziana Life Sciences CEO Discusses COVID-19 Trial Data in Exclusive Interview
Tiziana Reports Positive Data from the Clinical Study of Nasal Administration with Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, in COVID-19 Patients in Brazil
